Diversify Advisory Services LLC Invests $2.96 Million in Medpace Holdings, Inc. $MEDP

Diversify Advisory Services LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 5,016 shares of the company’s stock, valued at approximately $2,956,000.

Several other institutional investors also recently bought and sold shares of MEDP. Geneos Wealth Management Inc. boosted its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in shares of Medpace during the 4th quarter worth approximately $30,000. Allied Private Wealth LLC purchased a new position in shares of Medpace during the 2nd quarter valued at approximately $31,000. Basecamp Wealth Advisors LLC increased its holdings in shares of Medpace by 187.5% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after purchasing an additional 45 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Medpace in the 2nd quarter valued at $34,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO August J. Troendle sold 458 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $600.39, for a total transaction of $274,978.62. Following the transaction, the chief executive officer owned 603,978 shares of the company’s stock, valued at approximately $362,622,351.42. The trade was a 0.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Susan E. Burwig sold 7,500 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the sale, the vice president directly owned 62,984 shares of the company’s stock, valued at $37,790,400. This represents a 10.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 67,195 shares of company stock valued at $37,989,998 over the last 90 days. Insiders own 20.50% of the company’s stock.

Medpace Price Performance

MEDP opened at $590.30 on Wednesday. The company’s 50 day simple moving average is $541.49 and its two-hundred day simple moving average is $491.49. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The firm has a market capitalization of $16.48 billion, a price-to-earnings ratio of 34.60, a price-to-earnings-growth ratio of 2.58 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same period in the previous year, the firm posted $3.10 EPS. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on MEDP shares. Robert W. Baird increased their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and lifted their price objective for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Truist Financial upped their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Mizuho increased their target price on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Finally, Leerink Partners set a $620.00 target price on Medpace in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Medpace presently has an average rating of “Hold” and an average price target of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.